Simplex Trading
STRO icon

Simplex Trading’s Sutro Biopharma STRO Stock Holding History

Simplex Trading’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62
Closed -$1.93K – 10272
2026
Q1 		$1.54K Buy
+62
New +$1.12K ﹤0.01% 8464
2025
Q1 		– Sell
-135
Closed -$2.13K – 9634
2024
Q4 		$2K Sell
135
-349
-72% -$10.7K ﹤0.01% 8087
2024
Q3 		$16K Buy
484
+13
+3% +$510 ﹤0.01% 6856
2024
Q2 		$13K Buy
471
+365
+344% +$14.4K ﹤0.01% 7267
2024
Q1 		$6K Buy
106
+87
+458% +$3.84K ﹤0.01% 7946
2023
Q4 		$0 Buy
+19
New +$603 ﹤0.01% 9789
2022
Q4 		– Sell
-49
Closed -$2K – 10381
2022
Q3 		$2K Sell
49
-2,691
-98% -$159K ﹤0.01% 9365
2022
Q2 		$142K Buy
2,740
+2,700
+6,750% +$151K ﹤0.01% 5074
2022
Q1 		$3K Buy
+40
New +$3.81K ﹤0.01% 9742
2021
Q3 		– Sell
-2
Closed -$380 – 9883
2021
Q2 		$0 Sell
2
-711
-100% -$139K ﹤0.01% 10687
2021
Q1 		$162K Buy
+713
New +$169K ﹤0.01% 5064

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Simplex Trading's STRO Position: Q2 2026 in Review

Simplex Trading sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 62 shares — an estimated $1.93K sold.

Simplex Trading first reported a position in STRO in Q1 2021 and held it in 11 quarters. The position peaked at $162K in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Simplex Trading reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 62 Sutro Biopharma shares in Q2 2026, an estimated $1.93K.
  • Simplex Trading first reported a position in Sutro Biopharma in Q1 2021 and held it in 11 quarters.
  • Simplex Trading's Sutro Biopharma position peaked at $162K in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.